REFERENCES
- Ohgaki H, Kleihus P. Epidemiology and etiology of gliomas. Acta Neuropathol (Berl) 2005; 109: 93–108
- Fallon KB, Palmer CA, Roth KA, et al. Prognostic value of lp, 19q, 9p, 10q, and EGFR-FISH analyses in recurrent oligodendrogliomas. J Neuropathol Exp Neurol 2004; 63: 314–322
- Hoang-Xuan K, He J, Huguet S, et al. Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor pro-gression. Neurology 2001; 57: 1278–1281
- Bauman GS, Ino Y, Ueki K, et al. Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with
- oligodendrogliomas. Radiat Oncol Biol Phys 2000; 48: 825–830
- Chahlavi A, Kanner A, Peereboom D, et al. Impact of chromosome 1p status in response of oligodendroglioma to temozolomide: Preliminary results. J Neurooncol 2003; 61: 267–273
- Felsberg J, ErloNoh A, Sabel MC, et al. Oligodendroglial tumors: Refinement of candidate regions on chromosome arm 1p and correlation of 1p/19q status with survival. Brain Pathol 2004; 14: 121–130
- Reifenberg G, Louis DN. Oligodendroglioma: Toward molecular definitions in diagnostic neuro-oncology. J Neuropathol Exp Neurol 2003; 62: 111–126
- van den Bent MJ, Looijenga LH, Langberg K, et al. Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. Cancer 2003; 97: 1276–1284
- Idbaih A, Marie Y, Pierron G, et al. Two types of chromosome lp losses with opposite significance in gliomas. Ann Neurol 2005; 58: 483-487
- Barbashina V, Salazar P, Holland EC, et al. Allelic losses at 1p36 and 19q13 in gliomas: Correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene. Clin Cancer Res 2005; 11: 1119–1128
- Alonso ME, Bello MJ, Arjona D, et al. Mutational study of the lp located genes p18ink4c, Patched-2, RIZ1 and KIF1B in oligoden-drogliomas. Oncol Rep 2005; 13: 539–542
- Megyesi JF, Kachur E, Lee DH, et al. Imaging correlates of molecular signatures in oligodendrogliomas. Clin Cancer Res 2004; 10: 4303–4306
- Zlatescu MC, TehraniYazdi A, Sasaki H, et al. Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms. Cancer Res 2001; 61: 6713–6715
- Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000; 343: 1350–1354
- Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352: 997–1003
- Breil M, Tortosa A, Verger E, et al. Prognostic significance of 06 Methyl-guanine-DNA Methyltransferase determined by promoter hypermethylation and immunoistochemical expression in anaplas-tic glioma. Clin Cancer Res 2005; 11: 5167–5174
- Nakamura M, Watanabe T, Yonekawa Y, et al. Promoter18 Moellemann M, Wolter M, Felsberg J, et al. Frequent
- methylation of the DNA repair gene MGMT in astrocytoma ispromoter hypermethylation and low expression of the
- frequently associated with G:C—>A:T mutations of the TP53 tumorMGMT gene in oligodendroglial tumors. Int] Cancer 2005; 113 suppressor gene. Carcinogenesis 2001; 22: 1715-1719379-385